ProKidney (PROK) Competitors

ProKidney logo
$1.04 -0.02 (-1.89%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+1.92%)
As of 11/20/2026 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PROK vs. INBX, NKTR, TYRA, OMER, and SLN

Should you buy ProKidney stock or one of its competitors? ProKidney's main competitors and comparable companies include Inhibrx Biosciences (INBX), Nektar Therapeutics (NKTR), Tyra Biosciences (TYRA), Omeros (OMER), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProKidney compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Inhibrx Biosciences presently has a consensus price target of $185.00, indicating a potential upside of 168.23%. ProKidney has a consensus price target of $10.00, indicating a potential upside of 861.54%. Given ProKidney's stronger consensus rating and higher probable upside, analysts plainly believe ProKidney is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx Biosciences
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

In the previous week, Inhibrx Biosciences had 3 more articles in the media than ProKidney. MarketBeat recorded 19 mentions for Inhibrx Biosciences and 16 mentions for ProKidney. Inhibrx Biosciences' average media sentiment score of -0.02 beat ProKidney's score of -0.10 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibrx Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
ProKidney
3 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inhibrx Biosciences has a beta of 4.03, suggesting that its stock price is 303% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibrx BiosciencesN/A -563.90% -80.38%
ProKidney -13,326.71%N/A -37.98%

ProKidney has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibrx Biosciences$2M509.31-$140.05M-$9.06N/A
ProKidney$890K353.34-$68.99M-$0.60N/A

Summary

ProKidney beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

How does ProKidney compare to Nektar Therapeutics?

ProKidney (NASDAQ:PROK) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ProKidney has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProKidney$890K353.34-$68.99M-$0.60N/A
Nektar Therapeutics$55.23M18.71-$164.08M-$6.46N/A

ProKidney has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Nektar Therapeutics has a net margin of -339.67% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProKidney-13,326.71% N/A -37.98%
Nektar Therapeutics -339.67%-29.31%-22.32%

In the previous week, Nektar Therapeutics had 10 more articles in the media than ProKidney. MarketBeat recorded 26 mentions for Nektar Therapeutics and 16 mentions for ProKidney. Nektar Therapeutics' average media sentiment score of 0.40 beat ProKidney's score of -0.10 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProKidney
3 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nektar Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

ProKidney currently has a consensus price target of $10.00, indicating a potential upside of 861.54%. Nektar Therapeutics has a consensus price target of $130.33, indicating a potential upside of 331.57%. Given ProKidney's stronger consensus rating and higher possible upside, research analysts plainly believe ProKidney is more favorable than Nektar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Nektar Therapeutics
1 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.69

Summary

ProKidney beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Tyra Biosciences?

ProKidney (NASDAQ:PROK) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

ProKidney has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, ProKidney had 13 more articles in the media than Tyra Biosciences. MarketBeat recorded 16 mentions for ProKidney and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.21 beat ProKidney's score of -0.10 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProKidney
3 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tyra Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

51.6% of ProKidney shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tyra Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ProKidney-13,326.71% N/A -37.98%
Tyra Biosciences N/A -40.12%-37.62%

ProKidney currently has a consensus target price of $10.00, indicating a potential upside of 861.54%. Tyra Biosciences has a consensus target price of $47.50, indicating a potential upside of 136.08%. Given ProKidney's higher possible upside, equities analysts plainly believe ProKidney is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

ProKidney has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProKidney$890K353.34-$68.99M-$0.60N/A
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A

Summary

ProKidney beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Omeros?

Omeros (NASDAQ:OMER) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Omeros has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

In the previous week, Omeros had 25 more articles in the media than ProKidney. MarketBeat recorded 41 mentions for Omeros and 16 mentions for ProKidney. Omeros' average media sentiment score of 0.34 beat ProKidney's score of -0.10 indicating that Omeros is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
5 Very Positive mention(s)
7 Positive mention(s)
16 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
ProKidney
3 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Omeros has higher earnings, but lower revenue than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmerosN/AN/A-$3.35M$0.9613.76
ProKidney$890K353.34-$68.99M-$0.60N/A

Omeros presently has a consensus target price of $30.33, suggesting a potential upside of 129.62%. ProKidney has a consensus target price of $10.00, suggesting a potential upside of 861.54%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Omeros.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

48.8% of Omeros shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Omeros has a net margin of 0.00% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -251.94% 71.60%
ProKidney -13,326.71%N/A -37.98%

Summary

Omeros beats ProKidney on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Silence Therapeutics?

ProKidney (NASDAQ:PROK) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

ProKidney has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProKidney$890K353.34-$68.99M-$0.60N/A
Silence Therapeutics$560K2,198.56-$88.61M-$1.07N/A

ProKidney presently has a consensus price target of $10.00, suggesting a potential upside of 861.54%. Silence Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 21.15%. Given ProKidney's stronger consensus rating and higher probable upside, research analysts clearly believe ProKidney is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, ProKidney had 13 more articles in the media than Silence Therapeutics. MarketBeat recorded 16 mentions for ProKidney and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.51 beat ProKidney's score of -0.10 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProKidney
3 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ProKidney has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

Silence Therapeutics has a net margin of -8,943.86% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProKidney-13,326.71% N/A -37.98%
Silence Therapeutics -8,943.86%-56.32%-32.42%

51.6% of ProKidney shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ProKidney beats Silence Therapeutics on 11 of the 16 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PROK vs. The Competition

MetricProKidneyBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$314.48M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio-1.7323.0732.5628.72
Price / Sales353.3415.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book-0.354.124.343.51
Net Income-$68.99M-$24.08M$3.51B$394.12M
7 Day Performance-0.48%-9.85%-8.07%-8.97%
1 Month Performance-27.27%-12.77%-10.29%-11.61%
1 Year Performance-52.51%-7.99%-4.70%-11.21%

ProKidney Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PROK
ProKidney
1.6162 of 5 stars
$1.04
-1.9%
$10.00
+861.5%
-52.5%$314.48M$890KN/A231
INBX
Inhibrx Biosciences
3.0125 of 5 stars
$90.59
0.0%
$197.50
+118.0%
-17.8%$1.33BN/AN/A110
NKTR
Nektar Therapeutics
2.3081 of 5 stars
$38.44
+1.7%
$130.67
+239.9%
-44.4%$1.29B$54.59MN/A63
TYRA
Tyra Biosciences
2.8024 of 5 stars
$20.97
-0.1%
$47.40
+126.0%
-4.7%$1.25BN/AN/A87
OMER
Omeros
3.0776 of 5 stars
$18.15
+4.9%
$30.33
+67.1%
+48.9%$1.25B$38.42M14.18175

Related Companies and Tools


This page (NASDAQ:PROK) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners